GenScript ProBio to manufacture clinical trial batches of Synimmune's lead antibody drug
The CDMO will manufacture drug substance and drug product for Phase II clinical trials in AML patients
GenScript ProBio, the biologics CDMO segment of GenScript, has signed a manufacturing agreement with Synimmune for its innovative Flysyn antibody project for clinical Phase II production.
The agreement covers the technology transfer and manufacturing of drug substance and drug product for clinical Phase II trials, said Dr Brian Min, CEO of GenScript ProBio.
Flysyn was recently evaluated in a Phase I/II study in Germany as a potential treatment for acute myeloid leukemia (AML) patients in complete remission.
GenScript ProBio claims its GMP manufacturing center is a true "zero-crossover, unidirectional flow" plant, which meets FDA, EMA and NMPA (The National Medical Products Administration) regulatory requirements. To ensure the manufacturing of multiple samples at the same time, strict physical isolation measures are adopted in the whole facility.
The CDMO now owns five independent large-scale cell culture GMP upstream production lines with a total culture volume of 2,600 L, and three independent downstream purification production lines. The company's annual production capacity can reach up to 104 batches per year.
Dr Martin Steiner, CEO of Synimmune said the company plans to test Flysyn in an international multicenter Phase II clinical study in AML patients to obtain additional indications for efficacy.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance